Artivion, Inc. $AORT Stock Position Lifted by GW&K Investment Management LLC

GW&K Investment Management LLC boosted its position in shares of Artivion, Inc. (NYSE:AORT – Free Report) by 67.7% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,332,672 shares of the company’s stock after buying an additional 538,194 shares during the quarter. GW&K Investment Management LLC’s holdings in Artivion were worth $30,412,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Allworth Financial LP increased its stake in shares of Artivion by 2,048.3% in the 3rd quarter. Allworth Financial LP now owns 1,246 shares of the company’s stock valued at $28,000 after buying an additional 1,188 shares during the period. Pinnacle Wealth Planning Services Inc. raised its position in shares of Artivion by 362.8% during the third quarter. Pinnacle Wealth Planning Services Inc. now owns 1,379 shares of the company’s stock worth $31,000 after acquiring an additional 1,081 shares during the last quarter. Versant Capital Management Inc lifted its stake in shares of Artivion by 38.0% during the third quarter. Versant Capital Management Inc now owns 2,119 shares of the company’s stock valued at $48,000 after acquiring an additional 584 shares during the period. Fulcrum Asset Management LLP acquired a new position in shares of Artivion during the third quarter valued at $49,000. Finally, Quantbot Technologies LP acquired a new position in shares of Artivion during the second quarter valued at $103,000. 86.37% of the stock is currently owned by institutional investors.

Artivion Stock Performance

Shares of Artivion stock opened at $18.20 on Friday. The firm has a fifty day moving average of $22.22 and a two-hundred day moving average of $27.83. The stock has a market capitalization of $887.98 million, a price-to-earnings ratio of 40.15 and a beta of 1.31. Artivion, Inc. has a 52 week low of $18.11 and a 52 week high of $48.25. The company has a debt-to-equity ratio of 0.82, a quick ratio of 3.02 and a current ratio of 4.42.

Artivion (NYSE:AORT – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.14. Artivion had a positive return on equity of 5.12% and a negative net margin of 3.65%. The business had revenue of $123.79 million for the quarter, compared to analyst estimates of $120.97 million.

Wall Street Analyst Weigh In

Several research firms recently issued reports on AORT. Jefferies Financial Group began coverage on Artivion in a report on Tuesday, October 20th. They issued a “buy” rating and a $31.00 price target on the stock. Citizens Jmp dropped their price objective on Artivion from $48.00 to $42.00 and set a “market outperform” rating for the company in a report on Friday, November 6th. Wall Street Zen downgraded shares of Artivion from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Artivion in a research report on Wednesday, November 4th. Finally, Canaccord Genuity Group reduced their target price on shares of Artivion from $40.00 to $30.00 and set a “buy” rating on the stock in a research note on Friday, November 6th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $39.00.

Read Our Latest Report on AORT

Insider Buying and Selling

In other Artivion news, SVP Andrew Green sold 11,480 shares of the stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $24.97, for a total value of $286,655.60. Following the transaction, the senior vice president owned 40,160 shares of the company’s stock, valued at approximately $1,002,795.20. This represents a 22.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders sold a total of 19,483 shares of company stock valued at $503,031 in the last ninety days. Corporate insiders own 6.30% of the company’s stock.

Artivion Company Profile

(Free Report)

Artivion, Inc. is a medical device company focused on treating aortic disease and supporting cardiac and vascular surgery. Its products include aortic stent grafts and surgical grafts, mechanical heart valves, and BioGlue, a surgical adhesive used in cardiovascular procedures. The company was founded as CryoLife and adopted the Artivion name in 2022. It serves healthcare providers in the United States and international markets. Artivion is headquartered in Kennesaw, Georgia. Its chief executive officer is Pat Mackin.

Further Reading

Want to see what other hedge funds are holding AORT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Artivion, Inc. (NYSE:AORT – Free Report).

Institutional Ownership by Quarter for Artivion (NYSE:AORT)

Receive News & Ratings for Artivion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artivion and related companies with MarketBeat.com's FREE daily email newsletter.